AA
GPCR icon

ALPS Advisors’s Structure Therapeutics GPCR Stock Holding History

ALPS Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
71,833
+14,166
+25% +$627K 0.02% 348
2026
Q1 		$2.78M Buy
57,667
+7,941
+16% +$543K 0.01% 348
2025
Q4 		$3.46M Buy
49,726
+21,768
+78% +$889K 0.02% 304
2025
Q3 		$783K Sell
27,958
-3,115
-10% -$62K ﹤0.01% 608
2025
Q2 		$644K Sell
31,073
-12,007
-28% -$264K ﹤0.01% 593
2025
Q1 		$746K Sell
43,080
-3,220
-7% -$78.9K ﹤0.01% 541
2024
Q4 		$1.26M Buy
+46,300
New +$1.64M 0.01% 434

Other funds holding GPCR

Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
BPMC
Buckland Partners Management Co Harrison, New York $204M AUM

ALPS Advisors's GPCR Position: Q2 2026 in Review

ALPS Advisors increased its Structure Therapeutics (GPCR) stake by 25% in Q2 2026, buying an estimated $627K and bringing the position to 71,833 shares worth $3.86M. The position accounts for 0.02% of the portfolio, ranked #348.

ALPS Advisors first reported a position in GPCR in Q4 2024 and has held it in 7 quarters since. 58 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • ALPS Advisors held 71,833 shares of Structure Therapeutics worth $3.86M as of Q2 2026.
  • ALPS Advisors bought 14,166 Structure Therapeutics shares in Q2 2026, an estimated $627K.
  • Structure Therapeutics made up 0.02% of ALPS Advisors's portfolio in Q2 2026, its #348 holding.
  • ALPS Advisors first reported a position in Structure Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 58 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.